9 research outputs found
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors:Findings from a phase 1/1b study
SAR439459 (SAR'459), a “second-generation” human anti-transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459 ± cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3 weeks (Q2W, Q3W) alone (Part 1A) or with 3 mg/kg cemiplimab Q2W or 350 mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5 mg/kg SAR'459. In Part 2B (dose expansion), 22.5 mg/kg SAR'459 and 350 mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty-eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5 mg/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness-of-fit plots and adequately described the observed data by a two-compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment-emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.</p
Surgical treatment of partial and full distal biceps tendon ruptures
Purpose: This study presents a series of cases with surgically treated partial distal biceps tendon ruptures. The results of full distal biceps tendon rupture repair are also presented and a comparison is made between the two groups.Methods: Between 2001 and 2015, patients with partial and full ruptures of the distal biceps tendon were surgically repaired. At follow-up, the elbow function of the patients was assessed using the Oxford Elbow Score and maximum flexion and supination forces were measured.Results: Forty-eight elbows in 43 patients returned to the follow-up visit. There was no statistically significant difference between the two groups in terms of function and strength.Conclusions: In this study, there were no statistical differences in outcome between the partial and the full distal biceps tendon groups. Surgical repair seems to be a valuable treatment option for partial distal biceps tendon ruptures
Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features.
Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Abstract SAR439459, a ‘second‐generation’ human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody, inhibits all TGFβ isoforms and improves the antitumor activity of anti‐programmed cell death protein‐1 therapeutics. This study reports the pharmacodynamics (PD) and biomarker results from phase I/Ib first‐in‐human study of SAR439459 ± cemiplimab in patients with advanced solid tumors (NCT03192345). In dose‐escalation phase (Part 1), SAR439459 was administered intravenously at increasing doses either every 2 weeks (Q2W) or every 3 weeks (Q3W) with cemiplimab IV at 3 mg/kg Q2W or 350 mg Q3W, respectively, in patients with advanced solid tumors. In dose‐expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5/7.5 mg/kg or at 22.5 mg/kg with cemiplimab 350 mg IV Q3W. Tumor biopsy and peripheral blood samples were collected for exploratory biomarker analyses to assess target engagement and PD, and results were correlated with patients' clinical parameters. SAR439459 ± cemiplimab showed decreased plasma and tissue TGFβ, downregulation of TGFβ‐pathway activation signature, modulation of peripheral natural killer (NK) and T cell expansion, proliferation, and increased secretion of CXCL10. Conversion of tumor tissue samples from ‘immune‐excluded’ to ‘immune‐infiltrated’ phenotype in a representative patient with melanoma SAR439459 22.5 mg/kg with cemiplimab was observed. In paired tumor and plasma, active and total TGFβ1 was more consistently elevated followed by TGFβ2, whereas TGFβ3 was only measurable (lower limit of quantitation ≥2.68 pg/mg) in tumors. SAR439459 ± cemiplimab showed expected peripheral PD effects and TGFβ alteration. However, further studies are needed to identify biomarkers of response
The worldwide antibiotic resistance and prescribing in european children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children
Objectives: Previously, web-based tools for cross-sectional antimicrobial point prevalence surveys (PPSs) have been used in adults to develop indicators of quality improvement. We aimed to determine the feasibility of developing similar quality indicators of improved antimicrobial prescribing focusing specifically on hospitalized neonates and children worldwide. Methods: A standardized antimicrobial PPS method was employed. Included were all inpatient children and neonates receiving an antimicrobial at 8:00 am on the day of the PPS. Denominators included the total number of inpatients. A web-based application was used for data entry, validation and reporting. We analysed 2012 data from 226 hospitals (H) in 41 countries (C) from Europe (174H; 24C), Africa (6H; 4C), Asia (25H; 8C), Australia (6H), Latin America (11H; 3C) and North America (4H). Results: Of 17 693 admissions, 6499 (36.7%) inpatients received at least one antimicrobial, but this varied considerably between wards and regions. Potential indicators included very high broad-spectrum antibiotic prescribing in children of mainly ceftriaxone (ranked first in Eastern Europe, 31.3%; Asia, 13.0%; Southern Europe, 9.8%), cefepime (ranked third in North America, 7.8%) and meropenem (ranked first in Latin America, 13.1%). The survey identified worryingly high use of critically important antibiotics for hospital-acquired infections in neonates (34.9%; range from 14.2% in Africa to 68.0% in Latin America) compared with children (28.3%; range from 14.5% in Africa to 48.9% in Latin America). Parenteral administration was very common among children in Asia (88%), Latin America (81%) and Europe (67%). Documentation of the reasons for antibiotic prescribing was lowest in Latin America (52%). Prolonged surgical prophylaxis rates ranged from 78% (Europe) to 84% (Latin America). Conclusions: Simple web-based PPS tools provide a feasible method to identify areas for improvement of antibiotic use, to set benchmarks and to monitor future interventions in hospitalized neonates and children. To our knowledge, this study has derived the first global quality indicators for antibiotic use in hospitalized neonates and children
High Rates of Prescribing Antimicrobials for Prophylaxis in Children and Neonates: Results From the Antibiotic Resistance and Prescribing in European Children Point Prevalence Survey
Background. This study was conducted to assess the variation in
prescription practices for systemic antimicrobial agents used for
prophylaxis among pediatric patients hospitalized in 41 countries
worldwide.
Methods. Using the standardized Antibiotic Resistance and Prescribing in
European Children Point Prevalence Survey protocol, a cross-sectional
point-prevalence survey was conducted at 226 pediatric hospitals in 41
countries from October 1 to November 30, 2012.
Results. Overall, 17 693 pediatric patients were surveyed and 36.7% of
them received antibiotics (n = 6499). Of 6818 inpatient children, 2242
(32.9%) received at least 1 antimicrobial for prophylactic use. Of 11
899 prescriptions for antimicrobials, 3400 (28.6%) were provided for
prophylactic use. Prophylaxis for medical diseases was the indication in
73.4% of cases (2495 of 3400), whereas 26.6% of prescriptions were for
surgical diseases (905 of 3400). In approximately half the cases (48.7%
[1656 of 3400]), a combination of 2 or more antimicrobials was
prescribed. The use of broad-spectrum antibiotics (BSAs), which included
tetracyclines, macrolides, lincosamides, and sulfonamides/trimethoprim,
was high (51.8% [1761 of 3400]). Broad-spectrum antibiotic use for
medical prophylaxis was more common in Asia (risk ratio [RR], 1.322;
95% confidence interval [CI], 1.202-1.653) and more restricted in
Australia (RR, 0.619; 95% CI, 0.521-0.736). Prescription of BSA for
surgical prophylaxis also varied according to United Nations region.
Finally, a high percentage of surgical patients (79.7% [721 of 905])
received their prophylaxis for longer than 1 day.
Conclusions. A high proportion of hospitalized children received
prophylactic BSAs. This represents a clear target for quality
improvement. Collectively speaking, it is critical to reduce total
prophylactic prescribing, BSA use, and prolonged prescription